Connect with us

General Other

Norman Lear Breaks His Own Record For Oldest Emmy Winner With Second ‘Live In Front Of A Studio Audience’ Variety Special Prize

mm

Published

on

Norman Lear Breaks His Own Record For Oldest Emmy Winner With Second ‘Live In Front Of A Studio Audience’ Variety Special Prize

Last September at the Creative Arts Emmys, Norman Lear became the oldest Emmy winner in history with a victory in the category of Outstanding Variety Special (Live) for Live in Front of a Studio Audience: Norman Lear’s ‘All In the Family’ And ‘The Jeffersons’. He was 97 at the time.

A year later, Lear, 98, set a new benchmark with a repeat in the same category for the second installment of the Live In Front of a Studio Audience franchise, Live In Front Of A Studio Audience: ‘All In The Family’ And ‘Good Times’. 

The ABC special was recognized on Night 2 of the remote 2020 Creative Arts Emmy Awards. Lear accepted the award in a pre-taped Zoom speech alongside fellow executive producers Kerry Washington, Brent Miller, Justin Theroux, Eric Cook and director James Burrows.

As Lear repeated his Emmy win to beat his own record, the previous oldest Emmy winner title holder, Sir David Attenborough, also extended his Emmy winning streak this year, winning his third consecutive Outstanding Narrator Emmy last night. He is 94

A TV icon, Lear is a 16-time Emmy nominee with six statuettes to his name. Live in Front of a Studio Audience is a one-night-only event, which enlists all-star casts to perform episodes of Lear’s iconic sitcoms.

More from Deadline

Best of Deadline

Sign up for Deadline’s Newsletter. For the latest news, follow us on Facebook, Twitter, and Instagram.

mm

Christine founded Sports Grind Entertainment with an aim to bring relevant and unaltered Sports news to the general public with a specific view point for each story catered by the team. She is a proficient journalist who holds a reputable portfolio with proficiency in content analysis and research.

Christine founded Sports Grind Entertainment with an aim to bring relevant and unaltered Sports news to the general public with a specific view point for each story catered by the team. She is a proficient journalist who holds a reputable portfolio with proficiency in content analysis and research.

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

General Other

Democrats prepare bill limiting U.S. Supreme Court justice terms to 18 years

mm

Published

on

Democrats prepare bill limiting U.S. Supreme Court justice terms to 18 years

By Andrew Chung

NEW YORK (Reuters) – Democrats in of the House of Representatives will introduce a bill next week to limit the tenure of U.S. Supreme Court justices to 18 years from current lifetime appointments, in a bid to reduce partisan warring over vacancies and preserve the court’s legitimacy.

The new bill, seen by Reuters, would allow every president to nominate two justices per four-year term and comes amid heightened political tensions as Republican President Donald Trump prepares to announce his third pick for the Supreme Court after the death on Sept. 18 of Justice Ruth Bader Ginsburg, with just 40 days to go until the Nov. 3 election.

“It would save the country a lot of agony and help lower the temperature over fights for the court that go to the fault lines of cultural issues and is one of the primary things tearing at our social fabric,” said California U.S. Representative Ro Khanna, who plans to introduce the legislation on Tuesday, along with Representatives Joe Kennedy III of Massachusetts and Don Beyer of Virginia.

Partly due to rising life expectancies, justices serve increasingly long tenures, on average now more than 25 years.

Term limits for high court justices have for years had support from a number of legal scholars on both the right and the left. Several polls in recent years have also shown large majorities of the American public support term limits.

The bill – the Supreme Court Term Limits and Regular Appointments Act – is the first to try to set Supreme Court term limits by statute, according to Gabe Roth, the executive director of Fix the Court, a judicial transparency group whose campaign for high court term limits has been gaining attention.

Some legal observers, including those who favor term limits, say they must be accomplished through an amendment to the U.S. Constitution, which has been interpreted as requiring life tenure for federal judges and justices.

The bill seeks to avoid constitutional concerns by exempting current justices from the 18-year rule. Those appointed under term limits would become “senior” upon retirement and rotate to lower courts.

“That’s perfectly consistent with their judicial independence and having a lifetime salary and a lifetime appointment,” Khanna said.

(Reporting by Andrew Chung; Editing by Mary Milliken and Cynthia Osterman)

mm

Christine founded Sports Grind Entertainment with an aim to bring relevant and unaltered Sports news to the general public with a specific view point for each story catered by the team. She is a proficient journalist who holds a reputable portfolio with proficiency in content analysis and research.

Continue Reading

General Other

Johnson & Johnson Begins Final Stage Trial of COVID-19 Vaccine; Target Price $170

mm

Published

on

Johnson & Johnson Begins Final Stage Trial of COVID-19 Vaccine; Target Price $170

TipRanks

3 ‘Strong Buy’ Stocks With Over 7% Dividend Yield

Markets are volatile, there can be no doubt. So far this month, the S&P 500 has fallen 9% from its peak. The tech-heavy NASDAQ, which had led the gainers all summer, is now leading the on the fall, having lost 11% since September 2. The three-week tumble has investors worried that we may be on the brink of another bear market.The headwinds are strong. The usual September swoon, the upcoming election, doubts about another round of economic stimulus – all are putting downward pressure on the stock markets.Which doesn’t mean that there are no opportunities. As the old saw goes, “Bulls and bears can both make money, while the pigs get slaughtered.” A falling market may worry investors, but a smart strategy can prevent the portfolio from losing too much long-term value while maintaining a steady income. Dividend stocks, which feed into the income stream, can be a key part of such a strategy.Using the data available in the TipRanks database, we’ve pulled up three stocks with high yields – from 7% to 11%, or up to 6 times the average dividend found on the S&P 500 index. Even better, these stocks are seen as Strong Buys by Wall Street’s analysts. Let’s find out why.Williams Companies (WMB)We start with Williams Companies, an Oklahoma-based energy company. Williams controls pipelines connecting Rocky Mountain natural gas fields with the Pacific Northwest region, and Appalachian and Texan fields with users in the Northeast and transport terminals on the Gulf Coast. The company’s primary operations are the processing and transport of natural gas, with additional ops in crude oil and energy generation. Williams handles nearly one-third of all US commercial and residential natural gas use.The essential nature of Williams’ business – really, modern society simply cannot get along without reliable energy sources – has insulated the company from some of the economic turndown in 1H20. Quarterly revenues slid from $2.1 billion at the end of last year to $1.9 billion in Q1 and $1.7 billion in Q2. EPS in the first half was 26 cents for Q1 and 25 cents for Q2 – but this was consistent with EPS results for the previous three quarters. The generally sound financial base supported the company’s reliable dividend. Williams has been raising that payment for the past four years, and even the corona crisis could not derail it. At 40 cents per common share, the dividend annualizes to $1.60 and yields an impressive 7.7%. The next payment is scheduled for September 28.Truist analyst Tristan Richardson sees Williams as one of the midstream sector’s best positioned companies.“We continue to look to WMB as a defensive component of midstream and favor its 2H prospects as broader midstream grasps at recovery… Beyond 2020 we see the value proposition as a stable footprint with free cash flow generation even in the current environment. We also see room for incremental leverage reduction throughout our forecast period on scaled back capital plans and even with the stable dividend. We look for modestly lower capex in 2021, however unlike more G&P oriented midstream firms, we see a project backlog in downstream that should support very modest growth,” Richardson noted.Accordingly, Richardson rates WMB shares as a Buy, and his $26 price target implies a 30% upside potential from current levels. (To watch Richardson’s track record, click here)Overall, the Strong Buy analyst consensus rating on WMB is based on 11 Buy reviews against just a single Hold. The stock’s current share price is $19.91 and the average price target is $24.58, making the one-year upside potential 23%. (See WMB stock analysis on TipRanks)Magellan Midstream (MMP)The second stock on our list is another midstream energy company, Magellan. This is another Oklahoma-based firm, with a network of assets across much of the US from the Rocky Mountains to the Mississippi Valley, and into the Southeast. Magellan’s network transports crude oil and refined products, and includes Gulf Coast export shipping terminals.Magellan’s total revenues rose sequentially to $782.8 in Q1, and EPS came in at $1.28, well above the forecast. These numbers turned down drastically in Q2, as revenue fell to $460.4 million and EPS collapsed to 65 cents. The outlook for Q3 predicts a modest recovery, with EPS forecast at 85 cents. The company strengthened its position in the second quarter with an issue of 10-year senior notes, totaling $500 million, at 3.25%. This reduced the company’s debt service payments, and shored up liquidity, making possible the maintenance of the dividend.The dividend was kept steady at $1.0275 per common share quarterly. Annualized, this comes to $4.11, a good absolute return, and gives a yield of 11.1%, giving MMP a far higher return than Treasury bonds or the average S&P-listed stock.Well Fargo analyst Praneeth Satish believes that MMP has strong prospects for recovery. “[We] view near-term weakness in refined products demand as temporary and recovering. In the interim, MMP remains well positioned given its strong balance sheet and liquidity position, and ratable cash flow stream…” Satish goes on to note that the dividend appears secure for the near-term: “The company plans to maintain the current quarterly distribution for the rest of the year.”In line with this generally upbeat outlook, Satish gives MMP an Overweight (i.e. Buy) rating, and a $54 price target that implies 57% growth in the coming year. (To watch Satish’s track record, click here)Net net, MMP shares have a unanimous Strong Buy analyst consensus rating, a show of confidence by Wall Street’s analyst corps. The stock is selling for $33.44, and the average price target of $51.13 implies 53% growth in the year ahead. (See MMP stock analysis on TipRanks)Ready Capital Corporation (RC)The second stock on our list is a real estate investment trust. No surprise finding one of these in a list of strong dividend payers – REITs have long been known for their high dividend payments. Ready Capital, which focuses on the commercial mortgage niche of the REIT sector, has a portfolio of loans in real estate securities and multi-family dwellings. RC has provided more than $3 billion in capital to its loan customers.In the first quarter of this year, when the coronavirus hit, the economy turned south, and business came to a standstill, Ready Capital took a heavy blow. Revenues fell by 58%, and Q1 EPS came in at just one penny. Things turned around in Q2, however, after the company took measures – including increasing liquidity, reducing liabilities, and increasing involvement in government-sponsored lending – to shore up business. Revenues rose to $87 million and EPS rebounded to 70 cents.In the wake of the strong Q2 results, RC also started restoring its dividend. In Q1 the company had slashed the payment from 40 cents to 25 cents; in the most recent declaration, for an October 30 payment, the new dividend is set at 30 cents per share. This annualizes to $1.20 and gives a strong yield of 9.9%.Crispin Love, writing from Piper Sandler, notes the company’s success in getting back on track.“Given low interest rates, Ready Capital had a record $1.2B in residential mortgage originations versus our $1.1B estimate. Gain on sale margins were also at record levels. We are calculating gain on sale margins of 3.7%, up from 2.4% in 1Q20,” Love wrote.In a separate note, written after the dividend declaration, Love added, “We believe that the Board’s actions show an increased confidence for the company to get back to its pre-pandemic $0.40 dividend. In recent earnings calls, management has commented that its goal is to get back to stabilized earnings above $0.40, which would support a dividend more in-line with pre-pandemic levels.”To this end, Love rates RC an Overweight (i.e. Buy) along with a $12 price target, suggesting an upside of 14%. (To watch Love’s track record, click here)All in all, Ready Capital has a unanimous Strong Buy analyst consensus rating, based on 4 recent positive reviews. The stock has an average price target of $11.50, which gives a 9% upside from the current share price of $10.51. (See RC stock analysis on TipRanks)To find good ideas for dividend stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

mm

Christine founded Sports Grind Entertainment with an aim to bring relevant and unaltered Sports news to the general public with a specific view point for each story catered by the team. She is a proficient journalist who holds a reputable portfolio with proficiency in content analysis and research.

Continue Reading

General Other

Donald Trump’s Much-Hyped Health Care Plan Isn’t Much of a Plan at All

mm

Published

on

President Donald Trump delivers a speech about health care on Sept. 24, 2020 in Charlotte, North Carolina, less than six weeks before the November election.
President Donald Trump delivers a speech about health care on Sept. 24, 2020 in Charlotte, North Carolina, less than six weeks before the November election.

President Donald Trump delivers a speech about health care on Sept. 24, 2020 in Charlotte, North Carolina, less than six weeks before the November election. Credit – Brian Blanco—Getty Images

President Donald Trump, who has long promised a “beautiful” and “phenomenal” health care plan, announced a series of largely meaningless actions on Thursday during a speech in North Carolina that effectively served as a campaign event.

The most tangible proposal Trump unveiled was a vow to send $200 prescription drug discount cards to 33 million Medicare beneficiaries “in the coming weeks.” However, the President said the $6.6 billion outlay needed to fund this program would have to come from savings from his “most favored nations” drug pricing proposal, which he announced on Sept. 13, and which experts say would be close to impossible to implement before the November election.

The Trump Administration recently tried and failed to convince the pharmaceutical industry to fund a similar plan, according to the New York Times. It’s unclear if the version announced Thursday will see a different fate.

Trump also announced two non-binding executive orders on Thursday, one addressing the topic of surprise out-of-network medical bills and the other addressing the topic of protecting pre-existing conditions. These are two of Americans’ biggest complaints with the country’s health care system. But neither of these orders will have any immediate effect on the problem at hand.

The first non-binding executive order is simply a promise. It declares that “it is the policy of the United States that people who suffer from pre-existing conditions will be protected,” Health and Human Services Secretary Alex Azar said on a press call with reporters before Trump’s speech. This does not create a policy or a law. Administration officials and the President himself said this would cover the same protections already established under the Affordable Care Act (ACA)—the health care law passed by former President Barack Obama, which the Trump Administration is currently trying to overturn in court.

The U.S. Supreme Court is set to hear a challenge to the ACA on Nov. 10, one week after Election Day. If the High Court overturns the law, the American health care system would be sent into chaos. (That prospect is now more likely since Justice Ruth Bader Ginsburg has died and Trump has vowed to appoint a new judge to replace her as soon as possible.) The protections for those with pre-existing conditions that Trump is touting would evaporate, tens of millions of Americans would lose health insurance coverage and the current system of insurance marketplaces would disappear. Health care and legal experts noted that it’s unlikely the White House could put in place similar protections for people with pre-existing conditions without passing a law through Congress.

Trump, though, did not seem deterred. He told the often-cheering audience on Thursday that he was glad his Administration has been able to keep the ACA’s protections for pre-existing conditions even as Republicans successfully eliminated other provisions, like the so-called individual mandate. “We were able to terminate the individual mandate, but kept the provision protecting patients with pre-existing conditions,” Trump said.

This statement likely made the Trump Administration’s own Department of Justice (DOJ) lawyers squirm. In the current ACA case before the Supreme Court, DOJ lawyers are backing an argument that is at odds with the President’s words—that the Justices must find the entire ACA no longer constitutional since the individual mandate is no longer in effect.

And while Trump has often talked about protecting people with pre-existing conditions, his Administration has repeatedly taken actions that would have the opposite effect. The Administration has supported Congressional Republicans’ many attempts to repeal the ACA, which would eliminate protections for those with pre-existing conditions, and it championed cheaper, skimpier health insurance plans that allow insurers to deny coverage to those with pre-existing conditions.

The second non-binding executive order also does not commit Trump to taking action. Rather, it directs Azar to work with Congress to ban surprise out-of-network medical bills. If Congress does not pass legislation by Jan. 1, Azar told reporters, then Trump will direct him to take other actions. (Azar said he did not have other details on what those actions would be.)

Trump’s announcements Thursday failed to match his pledge of a “full and complete” health care plan. They also failed to make good on senior officials’ claims, made on the press call just ahead of Trump’s speech Thursday, that the President would present an “historic” proposal. But none of this came as much of a surprise to those in Washington or in the health care industry. Trump’s speech, less than six weeks before an election in which he’s trailing former Vice President Joe Biden in most polls, was widely viewed as another attempt to change the national conversation.

Trump is particularly lagging behind Biden on most health care issues, and surveys show that most Americans still disapprove of the President’s handling of the coronavirus pandemic. A new survey released by the Commonwealth Fund on Thursday found that the majority of likely voters in 10 battleground states said Biden is more likely to protect insurance coverage for pre-existing conditions. And a poll by the nonpartisan Kaiser Family Foundation this month found that the majority of voters trust Biden over Trump on a variety of health care issues, with the President only leading narrowly on prescription drug prices.

Trump’s top advisers, while striking an upbeat note before his event in North Carolina, demurred when asked for the details on how the President’s new plans would become reality. “It is what it is,” Azar said.

mm

Christine founded Sports Grind Entertainment with an aim to bring relevant and unaltered Sports news to the general public with a specific view point for each story catered by the team. She is a proficient journalist who holds a reputable portfolio with proficiency in content analysis and research.

Continue Reading

Trending